List of Excipients in Branded Drug PHENOXYBENZAMINE HYDROCHLORIDE

Company	Tradename	Ingredient	NDC	Excipient	Potential Generic Entry
Prasco Laboratories	PHENOXYBENZAMINE HYDROCHLORIDE	phenoxybenzamine hydrochloride	66993-066	D&C RED NO. 33
Prasco Laboratories	PHENOXYBENZAMINE HYDROCHLORIDE	phenoxybenzamine hydrochloride	66993-066	FD&C RED NO. 3
Prasco Laboratories	PHENOXYBENZAMINE HYDROCHLORIDE	phenoxybenzamine hydrochloride	66993-066	FD&C YELLOW NO. 6

Generic Drugs Containing PHENOXYBENZAMINE HYDROCHLORIDE

Company	Ingredient	NDC	Excipient
Hikma Pharmaceuticals USA Inc	phenoxybenzamine hydrochloride	0054-0349	AMMONIA
Hikma Pharmaceuticals USA Inc	phenoxybenzamine hydrochloride	0054-0349	ANHYDROUS LACTOSE
Hikma Pharmaceuticals USA Inc	phenoxybenzamine hydrochloride	0054-0349	BUTYL ALCOHOL

What are the Most Frequently-Used Excipients in PHENOXYBENZAMINE HYDROCHLORIDE?

# Of NDCs	Excipient
3	ALCOHOL
4	AMMONIA
4	ANHYDROUS LACTOSE

Phenoxybenzamine Hydrochloride Excipient Strategy and Commercial Opportunities

Last updated: August 7, 2026

Phenoxybenzamine hydrochloride is a mature, small-molecule alpha-adrenergic antagonist with limited active patent protection and a concentrated specialty market. Commercial value is more likely to come from reliable supply, differentiated dosage forms, pediatric and low-dose presentations, global registration, and excipient-driven product improvements than from new chemical-entity exclusivity. The primary U.S. reference product is Dibenzyline capsules, historically supplied as a 10 mg oral capsule for pheochromocytoma-related hypertension and sweating [1].

What is the commercial profile of phenoxybenzamine hydrochloride?

Phenoxybenzamine hydrochloride is an irreversible, nonselective alpha-adrenergic blocker. FDA-approved use centers on pheochromocytoma, particularly control of hypertension and sweating associated with catecholamine excess [1].

Attribute	Commercial relevance
Active ingredient	Phenoxybenzamine hydrochloride
Drug class	Irreversible alpha-adrenergic antagonist
Primary approved use	Pheochromocytoma-associated hypertension and sweating
Common U.S. dosage form	10 mg oral capsule
Patient population	Small, specialty, largely chronic or perioperative
Regulatory category	Small-molecule prescription drug
Biosimilar pathway	Not applicable
Main commercial constraint	Limited volume and supply concentration
Main differentiation opportunities	Dosage form, strengths, supply reliability, excipient compatibility, global access

The product is not a high-volume hypertension medicine. Its value is linked to a rare endocrine indication in which physicians may have few practical substitutes. Phenoxybenzamine is also used off-label in selected autonomic disorders, Raynaud-type vasospasm, and other alpha-adrenergic conditions, although off-label demand should not be treated as an approved-market forecast.

What excipients are used in phenoxybenzamine hydrochloride capsules?

Commercial capsule formulations generally use a conventional hard-gelatin capsule platform. Listed inactive ingredients for U.S. phenoxybenzamine hydrochloride capsule products have included lactose, starch-based excipients, magnesium stearate, gelatin, titanium dioxide, and colorants, depending on the manufacturer and product presentation [1,2].

A representative excipient architecture is:

Formulation function	Potential excipient class	Commercial purpose
Diluent	Lactose monohydrate or microcrystalline cellulose	Provides capsule fill mass
Filler and disintegrant	Corn starch, pregelatinized starch	Supports powder handling and capsule release
Lubricant	Magnesium stearate	Reduces adhesion during encapsulation
Capsule shell	Gelatin or hypromellose	Provides oral-dose enclosure
Opacifier	Titanium dioxide or equivalent	Controls appearance and light exposure
Colorant	Approved synthetic color or mineral pigment	Product identification
Flow aid	Colloidal silicon dioxide, where used	Improves powder flow and fill-weight control

The exact excipient composition is product-specific. Generic manufacturers must establish pharmaceutical equivalence and bioequivalence to the applicable reference product or use an alternative regulatory pathway where appropriate.

How should an excipient strategy address phenoxybenzamine hydrochloride?

The best excipient strategy should prioritize dose uniformity, chemical stability, capsule manufacturability, and patient acceptability. The active dose is relatively small, so the formulation must control segregation and fill-weight variability.

Dose uniformity and powder handling

A low-dose capsule can be vulnerable to content-uniformity problems when the API has poor flow or is present at a low percentage of total fill mass. A robust development program should evaluate:

• API particle-size distribution
• Bulk and tapped density
• Electrostatic behavior
• Segregation during blending and hopper transfer
• Lubrication time and magnesium stearate concentration
• Blend uniformity across commercial-scale batches

Pregelatinized starch can provide a useful combination of filler, binder, and disintegrant functionality. Microcrystalline cellulose may improve compactness and flow but can produce a different capsule fill density. Lactose offers cost efficiency and established supply, but lactose intolerance concerns and reducing-sugar reactivity must be assessed during compatibility work.

Chemical compatibility

Phenoxybenzamine hydrochloride should be tested against each proposed excipient under accelerated and long-term stability conditions. The work should include:

• API assay and degradation products
• Water activity and moisture uptake
• Capsule-shell brittleness
• Dissolution after storage
• Color change
• Extractables and leachables
• Compatibility with printing inks and blister materials

A lactose-free formulation could create a modest differentiation advantage if it maintains equivalent performance and supports broader use in patients with excipient sensitivities. It would also simplify positioning for hospital systems that standardize on low-allergen or simplified excipient products.

Capsule-shell selection

Hard gelatin capsules are the lowest-risk platform for a conventional generic. Hypromellose capsules can create a differentiated product where the manufacturer wants:

• A vegetarian capsule option
• Lower dependence on animal-derived materials
• Different moisture behavior
• Improved acceptance in selected international markets

The switch requires comparative evaluation of moisture transmission, shell brittleness, dissolution, storage conditions, and packaging. It should not be treated as a purely cosmetic change.

What formulations are protected or commercially differentiable?

The strongest practical opportunities are likely to involve formulation and presentation rather than composition-of-matter protection.

Immediate-release capsules

An immediate-release capsule with the same strength and route has the clearest regulatory path. Commercial differentiation may come from:

• 5 mg and 10 mg strengths
• Unit-dose blister packaging
• Calendar packaging for chronic use
• Child-resistant bottles
• Hospital-ready packaging
• Improved powder-flow manufacturing
• Lactose-free or hypromellose-shell formulations

A 5 mg strength could reduce tablet or capsule splitting and improve titration in patients who are sensitive to orthostatic hypotension, sedation, or reflex tachycardia. The commercial case depends on prescriber demand and whether the smaller strength can be supported economically in a low-volume market.

Oral liquid or suspension

An oral liquid could address pediatric use, feeding-tube administration, and patients unable to swallow capsules. Phenoxybenzamine’s physicochemical properties, chemical stability, taste, preservative compatibility, and adsorption to dosing devices would determine feasibility.

A liquid product would likely require a new formulation development program and may be more suitable for a 505(b)(2) application if the sponsor relies on published literature, reference-product data, or bridging studies rather than a conventional ANDA pathway. The product would need tightly controlled dosing because phenoxybenzamine has clinically important blood-pressure effects.

Potential excipient categories include:

• Buffered aqueous or hydroalcoholic vehicles
• Suspending agents
• Wetting agents
• Sweeteners
• Flavor systems
• Preservatives
• Antioxidants
• Chelating agents

The central technical risk is maintaining potency and uniformity across the labeled in-use period. A suspension would also require validated redispersibility and dose-delivery testing.

Modified-release formulations

Modified release has limited obvious clinical value because phenoxybenzamine is already used as a long-acting irreversible blocker. A controlled-release product could reduce peak-related adverse effects, but the clinical and regulatory burden would be high. The opportunity is therefore weaker than a low-dose capsule or oral liquid unless a sponsor has evidence of a meaningful tolerability advantage.

Compounded dosage forms

Compounding pharmacies may prepare noncommercial dosage forms for rare-disease patients, but compounded products do not provide the same quality system, labeling, or commercial scale as an FDA-approved product. A sponsor could target this unmet need with a registered oral liquid, lower-strength capsule, or tube-compatible formulation.

When does phenoxybenzamine hydrochloride lose exclusivity?

Phenoxybenzamine hydrochloride has been marketed for decades. The original product does not retain meaningful new-molecule exclusivity. The active ingredient’s core composition-of-matter protection expired long ago, and commercial competition is governed primarily by abbreviated approval, manufacturing capacity, product availability, and any product-specific patents or regulatory exclusivity.

Exclusivity category	Current commercial assessment
New chemical entity exclusivity	Expired
Core composition patent	Expected to be expired
Biosimilar exclusivity	Not applicable
Orphan-drug exclusivity	No current exclusivity identified for the established product
Formulation patents	Any surviving rights would be product-specific and require claim-level review
Method-of-use patents	Potentially relevant only if a later sponsor obtained enforceable claims
Regulatory moat	Limited; manufacturing and supply execution are more important

The relevant commercial question is not when the original molecule loses exclusivity. It is whether a new formulation, delivery system, or use patent can create enforceable differentiation.

What is the Orange Book status of phenoxybenzamine hydrochloride?

The FDA Orange Book identifies approved drug products and, where applicable, listed patents and exclusivity information [3]. Phenoxybenzamine hydrochloride is generally treated as an established genericized small molecule rather than a product with a current innovative exclusivity platform.

For a prospective sponsor, the Orange Book review should focus on:

1. The current reference-listed drug designation.
2. Approved strengths and dosage forms.
3. Active product listings and marketing status.
4. Any patent or exclusivity entries tied to a specific listed product.
5. Whether the proposed product is pharmaceutically equivalent to the reference product.

No broad, molecule-level Orange Book barrier is expected to prevent a conventional generic capsule. Any conclusion on a proposed product requires a current, product-specific Orange Book and patent-register review because listings and marketing status can change.

Are there Paragraph IV challenges involving phenoxybenzamine hydrochloride?

Paragraph IV litigation is less likely to be commercially significant for an old, low-volume drug than for a high-revenue branded medicine. A generic applicant could still submit a Paragraph IV certification if it believes a listed patent is invalid, unenforceable, or not infringed. The financial incentive depends on whether the reference product has active listed patents and whether the market can support litigation costs.

For phenoxybenzamine hydrochloride, the more probable pathway is a standard ANDA strategy based on patent certifications other than Paragraph IV, or a 505(b)(2) strategy for a differentiated dosage form. A Paragraph IV case would become material only if a sponsor introduced a new formulation or method-of-use product with current listed patent rights.

What patent litigation affects phenoxybenzamine hydrochloride?

No major, widely reported current U.S. patent litigation is associated with the established phenoxybenzamine capsule market in the public regulatory record reviewed for this analysis. The historical age of the product reduces the probability of an active core patent dispute.

Potential future litigation could involve:

• A liquid formulation
• A low-dose or pediatric presentation
• A novel capsule-shell or stability system
• A tube-administration formulation
• A newly approved method of use
• Trade secrets related to API sourcing or impurity control

A formulation patent would need claims that are technically narrow but commercially relevant. Broad claims covering conventional fillers, lubricants, gelatin capsules, or ordinary immediate-release compositions would face substantial validity and obviousness pressure.

What generic entry risks exist for phenoxybenzamine hydrochloride?

Generic entry risk is structurally high because the active ingredient is old and the dosage form is conventional. The more important risks are commercial and operational.

Risk	Effect on market entry
Small addressable market	Limits revenue available to support development
API supply concentration	Can create shortages or batch interruptions
Low dose and poor flow	Raises content-uniformity risk
Rare-disease demand variability	Complicates forecasting
Reference-product discontinuation or limited availability	Can complicate bioequivalence planning
Hospital purchasing pressure	Compresses price
Limited prescriber base	Slows adoption
Regulatory complexity for liquids	Increases development cost
Adverse-effect profile	Restricts broad off-label expansion

A generic capsule could enter with limited patent risk but still fail commercially if the market is too small, the API is expensive, or the manufacturer cannot maintain uninterrupted supply.

Which companies are positioned to challenge or supply the market?

The commercial field can include the branded reference-product holder, generic capsule manufacturers, contract manufacturers, specialty pharmaceutical companies, and compounding pharmacies. Public product availability varies by time and jurisdiction. Generic participation should be verified through current FDA approval listings, DailyMed records, wholesaler availability, and state or federal shortage databases.

The most credible entrants are manufacturers that already have:

• Hard-capsule capacity
• Controlled-substance or specialty-drug quality systems where required
• Access to qualified phenoxybenzamine hydrochloride API
• Small-batch commercial manufacturing capability
• U.S. ANDA infrastructure
• Specialty distribution relationships

A large generic company may have regulatory capability but limited interest because of the small market. A specialty company may accept lower volume if it can command a stable price and secure hospital or rare-disease distribution.

How strong is the patent estate for phenoxybenzamine hydrochloride?

The legacy patent estate is weak from an exclusivity perspective. The molecule is old, the main capsule platform is conventional, and no current broad composition patent is expected to block generic development.

Patent strength could be stronger for a genuinely differentiated product if claims cover:

• A defined impurity profile
• A specific polymorph with demonstrated performance benefits
• A stable aqueous formulation
• A pediatric concentration and dosing system
• A tube-compatible suspension
• A clinically meaningful pharmacokinetic profile
• A manufacturing process that produces a non-obvious quality advantage

Manufacturing know-how may be more valuable than patent rights. API impurity control, particle engineering, moisture management, and scale-up reproducibility can create practical barriers even when legal exclusivity is limited.

What licensing deals could support a phenoxybenzamine product?

Licensing opportunities are more likely to involve supply and distribution than proprietary drug technology. A commercial agreement could cover:

• Exclusive U.S. distribution of a specialty capsule
• Regional rights for Europe, Japan, or emerging markets
• Contract manufacture of a 5 mg or 10 mg capsule
• Co-development of an oral liquid
• API supply with minimum-volume commitments
• Hospital and rare-disease channel access

The economics favor an asset-light model if a sponsor can obtain a reliable API source and outsource manufacture under a quality agreement. A new formulation may justify a broader license only when clinical or regulatory differentiation is demonstrable.

How does phenoxybenzamine compare with competing alpha blockers?

Phenoxybenzamine differs from reversible alpha blockers such as doxazosin and prazosin because it produces prolonged, irreversible alpha-adrenergic blockade. That pharmacology remains clinically useful in selected pheochromocytoma settings, but it also creates tolerability and titration concerns.

Product	Mechanism	Typical commercial position
Phenoxybenzamine	Irreversible nonselective alpha blockade	Specialty, rare-disease, pheochromocytoma-focused
Doxazosin	Reversible alpha-1 blockade	Larger generic hypertension and urinary-tract market
Prazosin	Reversible alpha-1 blockade	Generic, multiple off-label uses
Phentolamine	Reversible alpha blockade	Acute or procedural settings, generally not a direct oral substitute

Phenoxybenzamine cannot compete on volume with broad-market alpha blockers. Its opportunity is based on clinical familiarity, rare-disease availability, and dependable supply.

What FDA regulatory pathway applies to new phenoxybenzamine formulations?

A conventional immediate-release capsule can generally be pursued through an ANDA if the product meets pharmaceutical-equivalence and bioequivalence requirements against the applicable reference product [4]. A liquid, altered-release product, new route, or materially different formulation may require a 505(b)(2) application.

Proposed product	Likely pathway
Same-strength immediate-release capsule	ANDA
Additional capsule strength	ANDA or other FDA-supported pathway, depending on reference-product status
Oral solution or suspension	Often 505(b)(2), subject to product-specific FDA assessment
Modified-release capsule	505(b)(2) or NDA-type development
New clinical use	505(b)(2) or supplemental application if linked to an approved sponsor product
Compounded preparation	Not an equivalent substitute for an approved commercial product

FDA development planning should address bioequivalence, dissolution, stability, extractables, capsule-shell compatibility, and dose uniformity. A liquid product would add in-use stability, dosing-device, microbiological, and palatability requirements.

What geographic opportunities exist for phenoxybenzamine hydrochloride?

The strongest geographic opportunity is in markets where pheochromocytoma diagnosis and endocrine surgery are established but product availability is inconsistent. A sponsor should evaluate:

• U.S. specialty distribution
• European national approvals and reimbursement
• Japan, where pheochromocytoma treatment demand is clinically established
• Middle Eastern markets with specialty hospital concentration
• Latin American markets where local registration and supply reliability may be limited

Geographic expansion is constrained by country-specific reference-product requirements, local pharmacopoeial standards, excipient restrictions, labeling rules, and reimbursement. A global capsule platform with a lactose-free option and adaptable capsule-shell specifications could reduce registration complexity.

What revenue exposure and launch scenarios are realistic?

Phenoxybenzamine is unlikely to support blockbuster economics without a major new indication or a broader clinical positioning strategy. Commercial value is more plausibly captured through a specialty-drug model.

Base-case capsule launch

A new 10 mg generic capsule would compete primarily on availability, price, and supply continuity. Revenue would likely be limited by the small patient population and existing generic competition.

Premium specialty launch

A sponsor could pursue a premium price for a product with documented supply reliability, smaller strength options, unit-dose packaging, or a differentiated capsule shell. The premium must be supported by specialty distribution and payer acceptance.

Pediatric or liquid launch

An oral liquid could address a narrower but less competitive segment. Its development cost and regulatory burden would be higher, but the product could receive stronger pricing if it solves administration problems for children or tube-fed patients.

Global supply platform

A manufacturer with qualified API, dual-source manufacturing, and regional distribution could create value through a portfolio approach rather than a single-product launch. Phenoxybenzamine could be bundled with other rare endocrine or perioperative medicines.

Key Takeaways

• Phenoxybenzamine hydrochloride is an old, genericized small molecule with limited core patent protection.
• The commercial market is small but clinically specialized, with value tied to availability and supply continuity.
• Conventional capsule generics face high legal entry feasibility but limited revenue potential.
• The most credible excipient opportunities are lactose-free capsules, hypromellose shells, lower strengths, improved flow systems, and unit-dose packaging.
• Oral liquid and tube-compatible formulations offer the clearest product differentiation but carry higher regulatory and stability risk.
• Biosimilar competition is irrelevant because phenoxybenzamine hydrochloride is a small molecule.
• A conventional immediate-release capsule is generally suited to an ANDA strategy; materially different formulations may require a 505(b)(2) application.
• Manufacturing know-how, API qualification, impurity control, and reliable specialty distribution may provide more practical protection than patents.
• The strongest commercial model is a specialty or global supply platform, not a high-volume primary-care launch.

FAQs About Phenoxybenzamine Hydrochloride Commercialization

Is phenoxybenzamine hydrochloride still protected by patents?

The original molecule and legacy product are not expected to retain meaningful composition-of-matter exclusivity. Any relevant current rights would likely be limited to a specific formulation, manufacturing process, or later method of use.

Can a company develop a 5 mg phenoxybenzamine capsule?

Yes. A 5 mg capsule could support more precise titration, but the regulatory pathway, reference-product strategy, content-uniformity data, and commercial demand would determine feasibility.

Would a liquid phenoxybenzamine product have market value?

Yes. An oral liquid could address pediatric, swallowing, and feeding-tube needs. Its value would depend on chemical stability, dose uniformity, palatability, regulatory pathway, and reimbursement.

Is phenoxybenzamine hydrochloride subject to biosimilar competition?

No. It is a conventional small-molecule drug. Competition would come from generic drugs or differentiated reformulations, not biosimilars.

What is the main barrier to a new phenoxybenzamine product?

The main barrier is commercial scale rather than patent exclusivity. A sponsor must justify development and manufacturing costs in a rare-disease market while maintaining reliable API supply and regulatory-quality production.

References

1. U.S. Food and Drug Administration. (2023). Dibenzyline (phenoxybenzamine hydrochloride) capsules prescribing information. FDA/DailyMed.

2. National Library of Medicine. (2024). Phenoxybenzamine hydrochloride capsule product labeling. DailyMed.

3. U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations: Orange Book. FDA.

4. U.S. Food and Drug Administration. (2024). ANDA submissions: Content and format. FDA.